Joint analysis of PK and immunogenicity outcomes using factorization model − a powerful approach for PK similarity study

Biological products, whether they are innovator products or biosimilars, can incite an immunogenic response ensuing in the development of anti-drug antibodies (ADA). The presence of ADA’s often affects the drug clearance, resulting in an increase in the variability of pharmacokinetic (PK) analysis a...

Descripción completa

Detalles Bibliográficos
Autores principales: Haliduola, Halimu N., Berti, Fausto, Stroissnig, Heimo, Guenzi, Eric, Otto, Hendrik, Sattar, Abid, Mansmann, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547438/
https://www.ncbi.nlm.nih.gov/pubmed/36209046
http://dx.doi.org/10.1186/s12874-022-01742-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547438/
https://www.ncbi.nlm.nih.gov/pubmed/36209046
http://dx.doi.org/10.1186/s12874-022-01742-2

Ejemplares similares